Overview
Drug discovery company developing non-hallucinogenic psychoplastogenic compounds that promote neural plasticity similar to psychedelics without the perceptual effects. Their TrkB-targeting molecules aim to treat depression, addiction, and neurological disorders.
More in Psychedelics
Latest industry news
Closed-Loop BCIs Charted as Next Frontier for Depression, Anxiety, and PTSD Treatment
2026-07-21 ยท Research
Instruments of Self-Knowledge: How Cognitive Assessment Tech Is Making the Invisible Mind Measurable
2026-07-21 ยท Industry
Top 10 Technologies Turning Self-Awareness Into Something You Can Actually See
2026-07-21 ยท Industry
China Clears Brain-Computer Interfaces for Commercial Use, Prompting Calls for Global Regulatory Alignment
2026-07-20 ยท Policy
Company details
Category
๐ Psychedelics
Location
Boston, MA, USA
Funding
Series A ยท $70M
Website
delix.comListed
2026-06-15
Is this your company?
Claim this listing to add your logo, full description, team, and products. Premium listings get featured placement.
Claim & upgrade listingAdvertise
Reach neurotech professionals
Newsletter sponsorships, featured listings, and sponsored articles.
View packages โ